Eli Lilly is leading in the GLP-1 field, with strong momentum. Novo Nordisk is working to catch up, but Eli Lilly remains the top player. GLP-1 medicines are popular, with breakthroughs in weight management driving sales. Eli Lilly’s Trulicity faces competition from newer compounds like tirzepatide, which is proving effective in treating diabetes, obesity, and sleep apnea.

Tirzepatide is a rapidly growing best-selling drug, mimicking GLP-1 and GIP actions for insulin secretion. Eli Lilly has other candidates in the pipeline, like orforglipron and retatrutide, which could strengthen its lead in the market. Novo Nordisk, once the leader, is now facing market share loss to Eli Lilly and compounding pharmacies.

Despite Novo Nordisk’s efforts to regain market share, Eli Lilly’s momentum with tirzepatide remains strong. Eli Lilly generates higher revenue and is a better buy than Novo Nordisk. Novo Nordisk is focusing on label expansions for semaglutide and has a robust pipeline with new offerings like amycretin.

Novo Nordisk is offering Wegovy and Ozempic at a reduced price, aiming to regain market dominance. However, Eli Lilly’s momentum with tirzepatide is challenging for Novo Nordisk. Eli Lilly’s revenue growth outpaces its peers, although Novo Nordisk has a more favorable valuation. Both companies have promising futures in the growing weight loss market.

Considerations before investing in Eli Lilly include Stock Advisor’s recommended top 10 stocks, excluding Eli Lilly. Eli Lilly’s revenue growth and earnings performance justify its valuation, while Novo Nordisk offers potential with its GLP-1 portfolio and pipeline. Stock Advisor has a history of market-crushing returns compared to the S&P 500.

Read more at Yahoo Finance: 2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?